ArticleArthroplasty today2026
The Economic Impact and Clinical Benefits of Intraosseous Injections in Total Knee Arthroplasty.
Article in Arthroplasty today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Periprosthetic joint infection (PJI) following total knee arthroplasty (TKA) causes significant morbidity and incurs a substantial economic burden on the healthcare system. Recent studies have demonstrated that intraosseous vancomycin (IOV) can reduce the rate of PJI in both primary and aseptic revision TKA when compared to intravenous vancomycin (IVV). This study evaluated the economic impact associated with IOV and IVV administration during primary and aseptic revision TKA. Methods: Published institutional hospitalization cost data for PJI following TKA utilizing the Nationwide Inpatient Sample were adjusted to 2024 inflation rates to estimate the treatment cost of one knee PJI. Institutional costs for IOV and IVV were calculated using Medicare rates for current procedural terminology code 36680 as well as the costs of instrumentation, medications, and additional operating room time. Published PJI rates with (primary 0.54%, aseptic revision 1.86%) and without (primary 1.08%, aseptic revision 4.89%) IOV were used to calculate the number needed to treat to prevent one PJI. Results: The cost per case was $177.04 for IOV and $3.90 for IVV. The inflation-adjusted cost per PJI treatment was $33,295.70. The number needed to treat to prevent one PJI for primary TKA was 185.2 and 33.0 for aseptic revision TKA. For primary TKA, utilizing IOV resulted in a cost savings of $1230.17 to prevent one PJI. For aseptic revision TKA, utilizing IOV resulted in a cost savings of $27,582.08. Conclusions: Utilizing IOV during both primary and aseptic revision TKA was shown to be cost-effective. The economic impact of PJI may be greater if additional costs, such as specialist visits, postoperative rehabilitation, and quality of life factors, are factored in.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.